Hyperkalemia Clinical Trial
Official title:
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Clinical Trial to Investigate the Efficacy and Safety of WS016 in the Patients With Hyperkalemia
The goal of this clinical trial is to evaluate the efficacy of different doses of WS016(3g, 6g and 12g) orally administered three times a day for 48 hours (acute treatment phase) vs placebo in the treatment of hyperkalemia, and to evaluate the efficacy of WS016(3g, 6g and 12g) orally administered once daily for 12 days ( maintenance treatment phase) vs placebo in maintaining normokalemia in participants have returned to normokalemia after the acute treatment phase.
The study plan includes approximately 140 participants who will be randomly assigned to the WS016 and placebo treatment groups. Participants will begin a 48-hour acute treatment phase with three times-daily oral administrations. After the 48-hour acute treatment, participants have returned to normokalemia will be randomly assigned again to enter a 12-day maintenance treatment phase with once-daily oral administration. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03172702 -
Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia
|
Phase 3 | |
| Terminated |
NCT05056727 -
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
|
Phase 3 | |
| Completed |
NCT02609841 -
POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study
|
N/A | |
| Recruiting |
NCT04789239 -
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
|
Phase 2 | |
| Completed |
NCT05029310 -
Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients
|
Phase 4 | |
| Terminated |
NCT04443608 -
Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
|
Phase 4 | |
| Completed |
NCT02607085 -
REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study
|
N/A | |
| Completed |
NCT03283267 -
A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)
|
Phase 1 | |
| Recruiting |
NCT06036823 -
5 Versus 10 Units of Insulin in Hyperkalemia Management
|
Phase 4 | |
| Recruiting |
NCT05173584 -
Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects.
|
Phase 4 | |
| Completed |
NCT05184998 -
Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels
|
||
| Completed |
NCT01737697 -
Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia
|
Phase 3 | |
| Completed |
NCT01493024 -
Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia
|
Phase 2 | |
| Completed |
NCT04207203 -
Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study
|
N/A | |
| Completed |
NCT05382988 -
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
|
Phase 3 | |
| Completed |
NCT04217590 -
Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
|
Phase 3 | |
| Recruiting |
NCT03096561 -
Measurement of Serum Potassium Rate During Accidental Hypothermia.
|
N/A | |
| Completed |
NCT03326583 -
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
|
Phase 2 | |
| Completed |
NCT03528681 -
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.
|
Phase 3 | |
| Completed |
NCT02107092 -
Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.
|
Phase 3 |